This article is more than 5 years old. Information may no longer be current.

Valeant completes sale of filler, toxin rights to Galderma

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Valeant announced it has completed the sale of all rights owned or held by the company for filler and toxin assets to Galderma for $1.4 billion.

The transaction follows a previously announced agreement with Nestle S.A., which recently completed its acquisition of Galderma, and includes the rights to Restylane, Perlane, Emervel, Sculptra and Dysport, according to a company press release.

“Galderma has already built a strong franchise with Restylane, Perlane, Dysport and Emervel outside North America and, with the addition of Sculptra, will now have the ability to bring their expertise to the U.S. and Canada,” J. Michael Pearson, chairman and CEO of Valeant, said in a May press release.